Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
15.21
-0.32 (-2.06%)
Sep 3, 2026, 11:23 AM EDT - Market open
Design Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Design Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $21. The average 1-year stock price forecast is 38.07% higher than the current stock price, while the lowest is $20 (+31.49%) and the highest is $22 (+44.64%).
Price Target: $21 (+38.07%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Design Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Cantor Fitzgerald No rating | Cantor Fitzgerald | Buy Maintains $41 | Buy | Maintains | $41 | +166.54% | Aug 5, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $22 | Buy | Maintains | $22 | +44.64% | Aug 4, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $20 | Buy | Maintains | $20 | +31.49% | Aug 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $21 | Buy | Reiterates | $21 | +38.07% | Jun 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $20 | Buy | Maintains | $20 | +31.49% | May 27, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.36
from -1.22
EPS Next Year
-1.59
from -1.36
EPS and Forward PE are based on non-GAAP adjusted numbers.